Temsirolimus for locally advanced and metastatic breast cancer - horizon scanning review
NHSC
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
NHSC. Temsirolimus for locally advanced and metastatic breast cancer - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2005
Authors' objectives
This study aims to assess the potential for future impact of temsirolimus for locally advanced and metastatic breast cancer
Authors' conclusions
Temsirolimus (CCI-779) inhibits the protein mTOR kinase and prevents cell division and tumour growth. It is currently in phase III clinical trials in combination with letrozole for the first-line treatment of postmenopausal women with oestrogen and/or progesterone receptor positive locally advanced or metastatic (stage III/IV) breast cancer. Preliminary phase II results in combination with letrozole show objective response rates of between 23% and 67% for combination therapy at various doses and intervals, compared to 30% for letrozole monotherapy.
Antineoplastic Agents; Breast Neoplasms /drug therapy; Neoplasm Metastasis
Language Published
English
Country of organisation
England
English summary
An English language summary is available.
Address for correspondence
Department of Public Health&Epidemiology, The University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom. Tel: +44 121 414 7831; Fax: +44 121 414 2269; Email: c.packer@bham.ac.uk